Prime Medicine is a clinical-stage biopharmaceutical company developing a proprietary Prime Editing platform—a precise genome editing technology designed to correct disease-causing genes in vivo without creating permanent double-strand breaks. The company advances multiple therapeutic candidates targeting rare genetic diseases, particularly liver-directed programs for conditions such as Wilson Disease and Alpha-1 Antitrypsin Deficiency, as well as ex vivo T-cell therapeutics through strategic partnerships. Prime Medicine has not yet commercialized products or generated product revenue; it funds operations through collaboration payments and milestones from partners, equity offerings, and capital reserves, while expecting to incur substantial ongoing expenses for preclinical and clinical development activities.